Results from a Phase 2a trial suggest that adding atebimetinib to modified gemcitabine and nab-paclitaxel (mGnP) chemotherapy may improve outcomes for patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC).
Atebimetinib is a novel MEK inhibitor designed with a short half-life, allowing it to temporarily block cancer-growth signaling while reducing the toxicities and resistance often seen with earlier drugs targeting the same pathway.
Among evaluable patients, the confirmed objective response rate was 36% and the disease control rate reached 82%. Median progression-free survival was 8.3 months, while median overall survival reached 17.3 months, an encouraging result in a disease with historically poor survival outcomes.
The treatment appeared effective regardless of RAS or KRAS mutation subtype. Severe side effects commonly associated with MEK inhibitors were not observed, and most serious adverse events were linked to chemotherapy. Notably, 84% of patients maintained or gained weight after three months of treatment.
A global Phase 3 trial, MAPKeeper 301, is now recruiting to determine whether the combination can improve survival compared with standard chemotherapy alone.
窗体顶端
窗体底端